



FDA ALERT: Recall of Mitoxantrone by Hospira—Confirmed Subpotency and Out-of-specification

Hospira, Inc. has initiated a worldwide voluntary recall of 10 lots of MitoXANTRONE (both human and veterinary), due to confirmed subpotency and elevated impurity levels.

Affected lots were distributed to hospitals and veterinary clinics worldwide from February 2013 through November 2014.

[Read the FDA safety alert here.](#)

[Read the 2010 AAN evidence report “The efficacy and safety of mitoxantrone \(Novantrone\) in the treatment of multiple sclerosis” here.](#)

[Read the patient summary of the evidence report here.](#)